Global Nanobiotechnology Industry

• Publication date: March 2012
• Report size: 643 pages

This report analyzes the worldwide markets for Nanobiotechnology in US$ Million by the following Technology Segments: Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, & Other Nanomaterials), and Nanodevices/Tools. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period...

This report analyzes the worldwide markets for Nanobiotechnology in US$ Million by the following Technology Segments: Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, & Other Nanomaterials), and Nanodevices/Tools. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 117 companies including many key and niche players worldwide such as Aduro BioTech, Arrowhead Research Corporation, Calando Pharmaceuticals, Inc., Agilent Technologies Inc., Asklepios BioPharmaceutical Inc., Biosante Phosphate Pharmaceuticals, Inc., Celgene Corporation, Elan Pharmaceuticals, Elitech Group, Flamel Technologies, Inc., Gilead Sciences Inc., Life Technologies Corporation, NanoBio Corporation, Nanogen, Inc., Nanophase Technologies Corporation, pSivida Ltd., Sigma Aldrich Company, Starpharma Holdings Ltd., Dendritic Nanotechnologies, Inc., SkyePharma Pharmaceuticals, Unidym, Inc., and Zyvex Instruments LLC. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Global Nanotechnology Industry

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
1. Nanomaterials I-4
Solid Inorganic Nanoparticles I-4
Nanocomposites I-4
Nanostructured Materials and Membranes I-4
Nanotubes and Fullerenes I-4
Other Nanomaterials I-4
Nanoshells I-4
Nanohorns I-5
Nanocapsules I-5
2. Nanodevices/Tools I-5


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
A Curtain Raiser II-1
Nanobiotechnology - The Next Big Thing II-2
Nanotechnology & Biology Tie the Knot: “Two to Tango” II-4
Where Conventional Molecular Science Falls Short Nanobio
Steps In II-4
What’s The Obsession With Size? II-5
Why Analysis at the Cellular Level is Important? II-5
Lessons from Nature II-6
Dawn Breaks On Nanobiotechnology II-6
Table 1: Nanobiotechnology and Related Medical Applications
Market (2007): Percentage Share Breakdown of Activity
Distribution by Region and Organizational Set-Up (includes
corresponding Graph/Chart) II-7

Table 2: Percentage Breakdown of Number of Nanotechnology
Companies in Healthcare Industry Worldwide by Region/Country
(2008) (includes corresponding Graph/Chart) II-7

Table 3: Percentage Breakdown of Number of Nanotechnology
Companies in Healthcare Industry Worldwide by Type - Private
and Public Sector (2008) (includes corresponding Graph/Chart) II-7

Table 4: Percentage Breakdown of Number of Nanotechnology
Companies in Healthcare Industry Worldwide By Sector -
Therapeutics and Drug Delivery; Clinical Diagnostics; Drug
Discovery Tools and Biomedical Research; and Biomaterials and
Biomedical Implants (2008) (includes corresponding
Graph/Chart) II-8

Table 5: Percentage Breakdown of Number of Nanotechnology
Companies in The field of Therapeutics and Drug Delivery
Worldwide by Area - Targeted Nanoparticles, Solubility &
Reformulation, Sustained Release, Blood Brain Barrier,
Nanomaterial Therapeutics and Others (2008) (includes
corresponding Graph/Chart) II-8

Table 6: Percentage Breakdown of Number of Nanotechnology
Companies in the field Therapeutics Worldwide by Therapeutic
Area - Oncology, Infectious Diseases, Central Nervous System
Diseases, Nutraceuticals, Ophthalmology and Others (2008)
(includes corresponding Graph/Chart) II-9

Table 7: Percentage Breakdown of Number of Nanotechnology
Companies in the field of Clinical Imaging and Diagnostics
Worldwide by Area - Tags and Probes; Imaging Agents;
Biosensors and Bio-detection; and Instruments (2008)
(includes corresponding Graph/Chart) II-9
Demystifying the Intriguing World of Nanobiotech II-9
A Meeting Place of Medicine’s Best Solutions II-10
Nanobiotechnology Promises to Deliver Nanomedicine II-11
Nanobiotechnology to Become Viable for All Drug Development
Stages II-12
Nanobioproducts in R&D As of 2007 & 2008 II-13
List of Marketed Nanoparticle-Based Pharmaceutical Products
As of the Year 2007 II-13
Nanoparticles: The Foundation of Nanobiotechnology II-14
Improved Optical Properties and Stability of Nanoparticles II-14
Nanoemulsions II-15
Diagnosis & Treatment of Cancer II-15
The Promise of Nanobiotechnology II-16
Biological Weaponries Against Diseases Come in Small Packages II-16
Proffered Benefits of Nanobiotechnology II-17
Opportunity & Beyond II-17
Nanobiotechnology - Will it Live Up to the Expectations? II-18
The Future of Nanobiotechnology: Shape of Things to Come II-18
Nanobiotechnology: The Outer Limits II-18
Futuristics: A Rumination II-19
Nanobiotechnology In the Year 2015 II-20
Field of Nanodiagnostics II-20
Field of Regenerative Medicine II-20
Field of Targeted Drug Delivery II-20
Conclusions II-20

2. MARKET DYNAMICS II-21
Nanotechnology & the 2007-2009 Recession: A Review II-21
Nanobio Feels the Pinch or Does It ? : A Closer Look II-21
Will Growth in Europe Be Held Hostage by the Debt Crisis? II-22
Outlook II-22
Developing Countries to Rise Over the Horizon II-22
Table 8: Global Nanobiotechnology Market (2009): Percentage
Share Breakdown of Investments by Region (includes
corresponding Graph/Chart) II-23

Table 9: Worldwide Funding in Nanotechnology (2005 & 2010):
Percentage Breakdown of Value Investments by Region/Country:
A Comparison (includes corresponding Graph/Chart) II-23
Nanomaterials & Nanoparticles Witness Robust Activity II-24
Focus on Improved Performance to Bring New Manufacturing
Methods for Nanomaterials II-24
Private & Public Companies to Step Up Funding on Nanotechnology II-24
Table 10: Worldwide Government Funding in Nanotechnology
(2008-2015) (In US$ Billion) (includes corresponding
Graph/Chart) II-25
Increasing Awareness on Technology to Drive Growth II-25
Demand for Novel Products to Push Up Growth II-26
Nano-Enabled Drug Discovery Holds Tremendous Potential II-26
Consolidation Sharpens the Industry’s Edge II-26
The Regulatory Framework Evolves with the Technology II-26
Quantum Dot Patents Pose Legal Tangles II-27
Miniaturized Liquid Handling Becomes Progressive II-27
Trends in Nanotechnology Enabled Drug Delivery Systems II-28
Robust Growth On Cards II-28
Table 11: Global Nanotechnology-Enabled Drug Delivery
Systems Market (2015 (P)): Percentage Share Breakdown of
Nanoparticles, Dendrimers, Polymer Therapeutics and Other
Nanostructures (includes corresponding Graph/Chart) II-28
Patent Expiries: A Key Driver II-29
Nanotechnology Enabled Drug Delivery to Exhume Unused Drugs II-29

3. INDUSTRY CHALLENGES & ISSUES II-30
Challenges II-30
Commercial Exploration: A Treacherous Voyage II-31
Conventional Medicine to Contest Nanomedicine Adoption II-31
Nanomaterials Use: Weighed Down with Toxicity Concerns II-32
Production Issues Continue to Plague Nanobiotech Industry II-33
Lack of De Facto Standards: A Challenge to Reckon With II-33
Embroilment Over Ethical Issues II-34
Social Relevance II-35
Economic Relevance II-36

4. INDUSTRY STRUCTURE II-37
Industry Structure: A Quick Primer II-37
A Dissection of Select Segments II-37
Nanoparticles II-37
Nanotubes and Fullerenes II-38
Dendrimers II-38
A Peek Into the Regulatory Framework II-38
United States II-39
Europe II-39
A Closer Look at Regional Nano Efforts II-39
United States: Unraveling the Country’s Edge II-39
Table 12: Global Intellectual Property Rights in
Nanotechnology by Leading Countries (2007) (includes
corresponding Graph/Chart) II-40
Europe: Hot On the Heels of the US II-40
Germany II-41
France II-41
United Kingdom II-41
Scandinavia II-41
Japan: A Noteworthy Region II-42

5. NANOBIO’S EPOCHAL STRIDES IN MODERN MEDICINE II-43
A Primer II-43
Impact on Drug Delivery Systems II-43
Benefits Offered II-45
Drug Encapsulation II-45
High Level of Specificity II-45
Increase in Drug Solubility and Uptake II-45
Greater Usage Flexibility II-46
Impact On Molecular Diagnostic Imaging II-46
Seeing The Unseen II-46
Impact On Pharmaceutical Drug Formulations II-47
Impact On Therapeutics II-48
Silver Nanoparticles as Effective Antimicrobial Agents II-48
Modern Day Nanomedicine: A Current Scenario II-49
Nanomedicine: The Cynosure of All Eyes II-49
Drug Delivery Systems Epitomized by Nanomedicine II-50
Targeted NanoDrug Delivery & Release II-50
Active and Passive Targeting Mechanisms in Drug Delivery II-51
Sustained and Pulsatile Release Mechanisms in Drug Delivery II-51
A Peek Into Potential Nanobio Enabled Drug Carriers II-51
Micelles II-52
Liposomes II-52
Dendrimers & Liquid Crystals II-52
Nanoparticles II-52
Polymeric Nanoparticles II-53
Hydrogels II-53
Molecularly Imprinted Polymers II-53
Microelectromechanical Systems (MEMS) II-53
Nanosuspensions II-54
Fullerenes: A Platform for GenX Drug Delivery II-54
Types of Nano-Based Drug Delivery Systems, Related
Materials, and Structures II-55
Dynamics of Regenerative Medicine II-55
Tissue Engineering and Restorations II-56
Nanotechnology Enabled Diagnostics II-57
Promised Path Breaking Applications in Molecular Diagnostics
& Imaging II-57
In-Vitro Diagnostics II-58
Nanoprobes & Implantable Devices in In-vivo Imaging II-59
Nanocomposites in Molecular Labeling & Diagnostics II-60
Laboratory-on-a-Chip - A Revolutionary Technology in
Biomolecular Detection II-60
Biosensors - Heralding New Opportunities in Molecular
Diagnostics II-61
Nanobiosensors - A New Approach to Diagnostics Testing II-61
Despite Huge Potential Key Hurdles Remain in
Commercialization II-62
Magnetic Nanoparticles for Imaging Applications in MRI II-62
Dendrimers Promise Milestone Applications in MRI II-62
Conclusions II-63
Gauging the Real World Impact of Nanobiotech On Cancer: A Case
Study II-63
Quantum Dots Cock a Snook at Traditional Anti-Body Labeling
Agents II-64
Chemotherapeutic Reengineering & Gene Therapy: New Treatment
Regimes II-64
Laboratory-on-chip (LOC): A Platform for Cancer Diagnosis II-65

6. CONCEPTUAL OVERVIEW II-66
Nanotechnology: An Introduction II-66
A Revolution in the Making II-66
Nanobiotechnology: An Exposition II-67
Nanobiotechnology & Medicine II-67
Nanobiotechnology & Biofuels II-68
Global Nanobiotechnology Market (2005): Major Products II-68
Global Nanobiotechnology Market (2005): Major Products Under
Development II-69
Analysis of Major Technology Segments II-69
Nanomaterials II-69
Nanoparticles II-70
Nanoparticles in Labeling or Bio Tagging II-70
Nanoparticles as Biomarkers II-71
Classification of Nanoparticles II-71
Solid Nanoparticles II-71
Solid Lipid Nanoparticles II-71
Calcium Phosphate Nanoparticles II-71
Dendrimers II-72
Nanocomposites II-72
Lamellar Nanocomposites II-73
Nanostructured Materials and Membranes II-73
Nanotubes and Fullerenes II-73
Other Nanomaterials II-74
Nanoshells II-74
Nanohorns II-74
Nanocapsules II-74
Nanodevices II-75
Nanotools II-75
Select Nanotools II-75
Atomic Force Microscopes II-75
Hot Embossing Lithography II-76
Dip-Pen Nanolithography II-76

7. GLOBAL RESEARCH CENTERS AND INSTITUTIONS II-77
Centre for Biologic Nanotechnology (USA) II-77
Centre for Biological and Environmental Nanotechnology (USA) II-77
Institute of Bioengineering and Nanotechnology (Singapore) II-77
The Nanobiotechnology Center (USA) II-78
The Tyndall National Institute (Ireland) II-78

8. STRATEGIC CORPORATE DEVELOPMENTS II-79
Agilent Acquires BIOCIUS II-79
IDEX Inks Deal to Acquire Microfluidics II-79
NanoMech Takes Over Canano II-79
Arrowhead Sells Unidym to Wisepower II-80
MP Biomedicals Signs Agreement of Cooperation with Russian
Nanotechnology Corporation II-80
Bruker Acquires AFM and OIM Segments from Veeco II-80
Audax Inks an Agreement with Brown to Acquire Osteobiologic
Nanotechnology II-81
Celgene Acquires Abraxis II-81
ELITech Completes Assets Acquisition of Nanogen II-81
Life Technologies Acquires BioTrove II-82
GSK Inks License With NanoBio to Market NB-001 II-82
CPN Establishes New Medical Nanobiotechnology R&D Center II-82
IBM to Setup New Research Center in Wroclaw II-82
Life Technologies and Zymera Ink Licensing Deal for Quantum
Dots Technology II-83
APR Acquires Nanotechnology Platform Technology for Preparing
Biotechnology Products II-83
Lockheed Teams Up with IIT-Delhi for Nanobiotechnology Research II-83
Piedmont Triad to Institute Statewide Nanobiotech Center II-84

9. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-85
Biocon and Abraxis Introduce ABRAXANE in India II-85
Starpharma Launches a Research Reagent Kit II-85
Monash Enters Into a Deal with National Fabrication Facility
of Australia II-86
Taiwan Inks Nanotechnology Collaboration Deal with Australia II-86
Avanti Institutes New Targeted Drug Delivery Company, Chikujee
Therapeutics II-86
CytoViva Rolls Out New Research Tool for Nanotechnology II-87
Dabur Obtains DCGI Approval for Nanoxel in New Indications II-87
Researchers Discover New Nanoparticles for Treating Brain
Infection II-87
Capsulution Tests Nanoparticle-Based Drug Formulation for
Improved Bio-Availability II-88
Invitrogen Signs Agreement with Genisphere II-88
Sigma-Aldrich Signs Deal With Nanoco Technologies II-88
Unidym Sells First License Option for Patent Portfolio to MDA II-89
Unidym Spins Off Carbon Nanotubes Therapeutics Business into
Ensysce Biosciences II-89
Nacalai USA and Nano-C Enter into Collaboration Agreement for
HPLC Technology II-89
Advanced Materials Technology Obtains License for LBL®
Technology from Capsulution II-90
Nanogen and The Elitech Group Announce Merger II-90
NanoViricides Signs MCRADA Agreement with CDC for Rabies II-90
Manhattan Scientifics Acquires Metallicum II-91
HemCon Medical Technologies Acquires Alltracel Pharmaceuticals II-91
CN Probes Inks Agreement With a Leading MEMS Foundry II-91
PrimeGen Biotech LLC Enters into Corporate Alliance with Unidym II-92
Ondine Acquires Exclusive License from UCL Business II-92
Dabur Introduces Nanotechnology Based Anti-Cancer Drug
Delivery System - Nanoxel II-92
Mitsui Ties Up With NIOSH to Evaluate Safety of Carbon Nanotubes II-93
Unidym Merges with Carbon Nanotechnologies II-93

10. FOCUS ON SELECT GLOBAL PLAYERS II-94
Aduro BioTech (USA) II-94
Arrowhead Research Corporation (USA) II-94
Calando Pharmaceuticals, Inc. (USA) II-94
Agilent Technologies Inc (USA) II-95
Asklepios BioPharmaceutical Inc (USA) II-95
Biosante Phosphate Pharmaceuticals, Inc. (USA) II-95
Celgene Corporation (USA) II-95
Elan Pharmaceuticals, Inc. (USA) II-96
Elitech Group (France) II-96
Flamel Technologies, Inc. (France) II-96
Gilead Sciences Inc (USA) II-97
Life Technologies Corporation (USA) II-97
NanoBio Corporation (USA) II-97
Nanophase Technologies Corporation (USA) II-98
pSivida Ltd (Australia) II-98
Sigma Aldrich Company (USA) II-98
Starpharma Holdings Ltd. (Australia) II-99
Dendritic Nanotechnologies, Inc. (USA) II-99
SkyePharma Pharmaceuticals (UK) II-100
Unidym, Inc. (USA) II-100
Zyvex Instruments LLC (USA) II-100

11. GLOBAL MARKET PERSPECTIVE II-102
Table 13: World Recent Past, Current & Future Analysis for
Nanobiotechnology by Geographic Region - US, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) II-102

Table 14: World Historic Review for Nanobiotechnology by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-103

Table 15: World 15-Year Perspective for Nanobiotechnology by
Geographic Region - Percentage Breakdown of Revenues for US,
Japan, Europe, and Rest of World Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) II-104
Analytics by Product Segment II-105
Table 16: World Recent Past, Current & Future Analysis for
Nanomaterials by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) II-105

Table 17: World Historic Review for Nanomaterials by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-106

Table 18: World 15-Year Perspective for Nanomaterials by
Geographic Region - Percentage Breakdown of Revenues for US,
Japan, Europe, and Rest of World Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) II-107

Table 19: World Recent Past, Current & Future Analysis for
Solid Inorganic Nanoparticles by Geographic Region - US,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) II-108

Table 20: World Historic Review for Solid Inorganic
Nanoparticles by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) II-109

Table 21: World 15-Year Perspective for Solid Inorganic
Nanoparticles by Geographic Region - Percentage Breakdown of
Revenues for US, Japan, Europe, and Rest of World Markets for
Years 2003, 2011 & 2017 (includes corresponding Graph/Chart) II-110

Table 22: World Recent Past, Current & Future Analysis for
Nanocomposites by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) II-111

Table 23: World Historic Review for Nanocomposites by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-112

Table 24: World 15-Year Perspective for Nanocomposites by
Geographic Region - Percentage Breakdown of Revenues for US,
Japan, Europe, and Rest of World Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) II-113

Table 25: World Recent Past, Current & Future Analysis for
Nanostructured Materials & Membranes by Geographic Region -
US, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) II-114

Table 26: World Historic Review for Nanostructured Materials &
Membranes by Geographic Region - US, Japan, Europe, and Rest
of World Markets Independently Analyzed with Annual Revenue
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-115

Table 27: World 15-Year Perspective for Nanostructured
Materials & Membranes by Geographic Region - Percentage
Breakdown of Revenues for US, Japan, Europe, and Rest of World
Markets for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) II-116

Table 28: World Recent Past, Current & Future Analysis for
Nanotubes and Fullerenes by Geographic Region - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) II-117

Table 29: World Historic Review for Nanotubes and Fullerenes
by Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-118

Table 30: World 15-Year Perspective for Nanotubes and
Fullerenes by Geographic Region - Percentage Breakdown of
Revenues for US, Japan, Europe, and Rest of World Markets for
Years 2003, 2011 & 2017 (includes corresponding Graph/Chart) II-119

Table 31: World Recent Past, Current & Future Analysis for
Other Nanomaterials by Geographic Region - US, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) II-120

Table 32: World Historic Review for Other Nanomaterials by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-121

Table 33: World 15-Year Perspective for Other Nanomaterials by
Geographic Region - Percentage Breakdown of Revenues for US,
Japan, Europe, and Rest of World Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) II-122

Table 34: World Recent Past, Current & Future Analysis for
Nanodevices/Tools by Geographic Region - US, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) II-123

Table 35: World Historic Review for Nanodevices/Tools by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-124

Table 36: World 15-Year Perspective for Nanodevices/Tools by
Geographic Region - Percentage Breakdown of Revenues for US,
Japan, Europe, and Rest of World Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) II-125
Analytics by Application II-126
Table 37: World Recent Past, Current & Future Analysis for
Nanobiotechnology by Application - Pharmaceuticals, Medical
Devices, Medical Research and Others Independently Analyzed
with Annual Revenue Figures in US$ Million for Years 2008
through 2017 (includes corresponding Graph/Chart) II-126

Table 38: World 10-Year Perspective for Nanobiotechnology by
Application - Percentage Breakdown of Revenues for
Pharmaceuticals, Medical Devices, Medical Research and Others
for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) II-127


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Industry Overview III-1
Public Sector Funding III-1
Major Nanobiotechnology Institutions and Centers III-2
The Nanobiotechnology Center (NBTC) III-2
Key technological advances achieved by NBTC in recent years - III-2
Principal NBTC Partners III-2
Centre for Biologic Nanotechnology (CBN) III-3
Centre for Biological and Environmental Nanotechnology (CBEN) III-3
Regulatory Environment III-3
B.Market Analytics III-5
Table 39: US Recent Past, Current & Future Analysis for
Nanobiotechnology by Technology Segment - Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-5

Table 40: US Historic Review for Nanobiotechnology by
Technology Segment - Nanomaterials (Solid Inorganic
Nanoparticles, Nanocomposites, Nanostructured Materials &
Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
and Nanodevices/Tools Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-6

Table 41: US 15-Year Perspective for Nanobiotechnology by
Technology Segment -Percentage Breakdown of Revenues for
Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/Tools for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-7

2. JAPAN III-8
A.Market Analysis III-8
Public Sector Funding III-8
B.Market Analytics III-9
Table 42: Japanese Recent Past, Current & Future Analysis
for Nanobiotechnology by Technology Segment - Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-9

Table 43: Japanese Historic Review for Nanobiotechnology by
Technology Segment - Nanomaterials (Solid Inorganic
Nanoparticles, Nanocomposites, Nanostructured Materials &
Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
and Nanodevices/Tools Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-10

Table 44: Japanese 15-Year Perspective for Nanobiotechnology
by Technology Segment - Percentage Breakdown of Revenues for
Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/Tools for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-11

3. EUROPE III-12
A.Market Analysis III-12
Market Overview III-12
European Union Banks Heavily on Nanobiotechnology III-12
Nano2Life Network III-13
Major Nanobiotechnology Networks in Europe as of the Year
2006 III-14
Public Sector Funding III-14
Regulatory Environment III-14
Registration for Novel Nanobiotech Drugs Pose Major Bottlenecks III-15
Focus on Select Markets III-15
Germany III-15
France III-15
United Kingdom III-16
Russia III-16
Russian Biotech Players Eye Partnerships with Indian
Counterparts III-17
Rest of Europe III-18
Ireland III-18
Market Overview III-18
Key Research Institutions/Centers in Nanobiotechnology III-18
The Tyndall National Institute III-18
The Centre for Research on Adaptive Nanostructures and
NanoDevices III-19
The National Centre for Sensor Research III-19
The Sami Nasr Institute for Advanced Materials Science III-19
B.Market Analytics III-20
Table 45: European Recent Past, Current & Future Analysis
for Nanobiotechnology by Technology Segment - Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-20

Table 46: European Historic Review for Nanobiotechnology by
Technology Segment - Nanomaterials (Solid Inorganic
Nanoparticles, Nanocomposites, Nanostructured Materials &
Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
and Nanodevices/Tools Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-21

Table 47: European 15-Year Perspective for Nanobiotechnology
by Technology Segment - Percentage Breakdown of Revenues for
Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/Tools for Years 2003 2011 & 2017 (includes
corresponding Graph/Chart) III-22

4. REST OF WORLD III-23
A.Market Analysis III-23
Public Sector Funding III-23
Focus on Select Markets III-23
Australia III-23
Market Overview III-23
Major Institutions III-24
Commonwealth Scientific and Industrial Research
Organisation (CSIRO) III-24
India III-24
Market Overview III-24
Government Takes Big Initiatives to Promote
Nanobiotechnology III-24
Agriculture, Livestock Sectors to Warm Up to
Nanobiotechnology Benefits III-25
Korea III-25
Taiwan III-26
Nanotechnology in Medicine - Small Yet Growing Segment in
Taiwan III-27
Iran III-27
B.Market Analytics III-28
Table 48: Rest of World Recent Past, Current & Future
Analysis for Nanobiotechnology by Technology Segment -
Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/Tools Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-28

Table 49: Rest of World Historic Review for
Nanobiotechnology by Technology Segment - Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) III-29

Table 50: Rest of World 15-Year Perspective for
Nanobiotechnology by Technology Segment - Percentage
Breakdown of Revenues for Nanomaterials (Solid Inorganic
Nanoparticles, Nanocomposites, Nanostructured Materials &
Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
and Nanodevices/Tools for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-30


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 117 (including Divisions/Subsidiaries - 122)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 75
Canada 2
Japan 1
Europe 32
France 3
Germany 8
The United Kingdom 9
Rest of Europe 12
Asia-Pacific (Excluding Japan) 9
Middle-East 3
------------------------------------------